Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 1106Carcinoma, Renal Cell 412Urinary Bladder Neoplasms 280Kidney Neoplasms 177Neoplasm Metastasis 134Neoplasms 132Carcinoma, Non-Small-Cell Lung 109Carcinoma, Transitional Cell 108Breast Neoplasms 94Melanoma 90Ovarian Neoplasms 70Lung Neoplasms 67Colorectal Neoplasms 58Pancreatic Neoplasms 49Sarcoma 48Wilms Tumor 41Uterine Cervical Neoplasms 37Head and Neck Neoplasms 37Stomach Neoplasms 36Testicular Neoplasms 33Non-Muscle Invasive Bladder Neoplasms 33Esophageal Neoplasms 33Squamous Cell Carcinoma of Head and Neck 31Neuroblastoma 30Lymphoma, Non-Hodgkin 29Colonic Neoplasms 28Small Cell Lung Carcinoma 27Carcinoma, Hepatocellular 27Urethral Neoplasms 25Triple Negative Breast Neoplasms 23

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Ovarian × Genitourinary × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡